- Patient's Testimonial
A patient was 66 years old when he was diagnosed with Descending Colon cancer by the doctors in Dec.2009.
The patient started Dendritic Cell Therapy on the recommendation of doctors. The six doses were administered from 2/4/11 to 29/06/11 in the presence of Doctors.
A female patient was diagnosed with Sigmoid Colon Caner with liver Mets at the age of 42 in 2010. In due course of time she had gone very weak and her condition was deteriorating. She was given Chemotherapy twice, which deteriorated her condition further because of the complications of chemotherapy.
Apheresis (Originated from Ancient Greek ) is a medical technology in which the blood of a donor or patient is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation.
The components which are separated and withdrawn include:
- Plasma (plasmapheresis)
- Platelets (plateletpheresis)
- Leukocytes (leukapheresis)
- RBC (Erythrocytapheresis)
When the apheresis system is used for therapy the system is removing relatively small amounts of fluid (not more than 10.5 mL/kg body weight). That fluid must be replaced to keep correct intravascular volume. If a crystalloid like normal saline is used, the infusion amount should be triple what is removed as the three to one ratio of NS for plasma is needed to keep up oncotic pressure.
The COBEŽ SpectraT separates blood into its components by centrifugation. Based on specific gravity, the "heavy" RBC will pack along the outer wall of the channel, and the "light" plasma along the inner wall. The "buffy coat", a layer which contains the WBC and platelets, will be between the RBC and plasma. By centrifuging blood and exerting a specific G force, we are able to separate blood into its components and collect whatever portion we desire from the RBC/Plasma interface. However, the specific gravity of several of the cells is very similar, making a clean separation of one cell from another difficult.
- Peripheral venipuncture
- Subclavian catheter
- Femoral catheter
- Arteriovenous fistula
- Arteriovenous shunt
To prevent clotting, the extracorporeal blood must be anticoagulated at the first possible opportunity. The anticoagulant use for apheresis procedures is ACD-A. ACD-A contains citrate, which anticoagulates the blood in the tubing set by binding the calcium needed to activate the clotting cascade. Citrate is active only in the extracorporeal circuit, and is rapidly metabolized when the blood is returned to the patient.
- Platelet collection
- Granulocyte collection
- Lymphocyte collection
- Plasma collection
- Cell depletion
- Plasma exchange
- Red cell exchange
- Peripheral Blood Stem Cells
- Perioperative platelet collection